Repurposing azole antifungals into antileishmanials : Novel 3-triazolylflavanones with promising in vitro antileishmanial activity against Leishmania major
Copyright © 2018 Elsevier B.V. All rights reserved..
Previously, we have described a series of azole antifungals namely 3-(1,2,4-triazol-1-yl)flavanones (TFs) containing an N-(phenethyl)azole framework required for sterol 14α-demethylase (CYP51) inhibitory activity. Similar mechanism of action of azoles in fungi and protozoan parasites prompted us to investigate the potential effects of TFs against promastigote and amastigote forms of Leishmania major (L. major), as well as their toxicity against macrophages, apoptosis induction and in silico interactions with the target enzyme. All compounds showed more potent anti-parasitic activity against L. major in comparison with reference azole drug fluconazole and standard antileishmanial agent glucantime. Among the tested compounds, the 4-chloro derivative (TF-2) was found to be the most potent one, being about 13 times more potent than fluconazole against promastigotes. TF-2 decreased both mean infection rate of macrophages (MIR) and mean number of amastigotes per macrophages (MNAPM), significantly more than fluconazole (P < .001). Furthermore, the cytotoxicity assay against J774.A.1 macrophages revealed that this compound displays high selectivity against amastigotes over macrophages (SI = 30.21). The in silico study showed that TF-2 can properly accommodated in the active site of parasitic CYP51 and coordinated to the heme. The SAR analysis showed that the introduction of 4-chloro on 2-phenyl moiety results in the best profile of activity and selectivity. Accordingly, the compound TF-2 prototype can be considered as promising candidate for development of new antileishmanial agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Parasitology international - 69(2019) vom: 01. Apr., Seite 103-109 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keighobadi, Masoud [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.04.2019 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.parint.2018.12.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM292123671 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM292123671 | ||
| 003 | DE-627 | ||
| 005 | 20231225072407.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.parint.2018.12.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0973.xml |
| 035 | |a (DE-627)NLM292123671 | ||
| 035 | |a (NLM)30582997 | ||
| 035 | |a (PII)S1383-5769(17)30499-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Keighobadi, Masoud |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing azole antifungals into antileishmanials |b Novel 3-triazolylflavanones with promising in vitro antileishmanial activity against Leishmania major |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.04.2019 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier B.V. All rights reserved. | ||
| 520 | |a Previously, we have described a series of azole antifungals namely 3-(1,2,4-triazol-1-yl)flavanones (TFs) containing an N-(phenethyl)azole framework required for sterol 14α-demethylase (CYP51) inhibitory activity. Similar mechanism of action of azoles in fungi and protozoan parasites prompted us to investigate the potential effects of TFs against promastigote and amastigote forms of Leishmania major (L. major), as well as their toxicity against macrophages, apoptosis induction and in silico interactions with the target enzyme. All compounds showed more potent anti-parasitic activity against L. major in comparison with reference azole drug fluconazole and standard antileishmanial agent glucantime. Among the tested compounds, the 4-chloro derivative (TF-2) was found to be the most potent one, being about 13 times more potent than fluconazole against promastigotes. TF-2 decreased both mean infection rate of macrophages (MIR) and mean number of amastigotes per macrophages (MNAPM), significantly more than fluconazole (P < .001). Furthermore, the cytotoxicity assay against J774.A.1 macrophages revealed that this compound displays high selectivity against amastigotes over macrophages (SI = 30.21). The in silico study showed that TF-2 can properly accommodated in the active site of parasitic CYP51 and coordinated to the heme. The SAR analysis showed that the introduction of 4-chloro on 2-phenyl moiety results in the best profile of activity and selectivity. Accordingly, the compound TF-2 prototype can be considered as promising candidate for development of new antileishmanial agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 1,2,4-triazole | |
| 650 | 4 | |a 4-chromanone derivatives | |
| 650 | 4 | |a Antileishmanial activity | |
| 650 | 4 | |a Azole antifungals | |
| 650 | 4 | |a Leishmania major | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Antiprotozoal Agents |2 NLM | |
| 650 | 7 | |a Azoles |2 NLM | |
| 650 | 7 | |a Flavanones |2 NLM | |
| 650 | 7 | |a Fluconazole |2 NLM | |
| 650 | 7 | |a 8VZV102JFY |2 NLM | |
| 650 | 7 | |a Cytochrome P450 Family 51 |2 NLM | |
| 650 | 7 | |a EC 1.14.14.154 |2 NLM | |
| 700 | 1 | |a Emami, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Fakhar, Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Shokri, Azar |e verfasserin |4 aut | |
| 700 | 1 | |a Mirzaei, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini Teshnizi, Saeed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Parasitology international |d 1998 |g 69(2019) vom: 01. Apr., Seite 103-109 |w (DE-627)NLM096478845 |x 1873-0329 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2019 |g day:01 |g month:04 |g pages:103-109 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.parint.2018.12.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2019 |b 01 |c 04 |h 103-109 | ||